SLIDESHOW: Recent Data from LEO Pharma on Chronic Hand Eczema

LEO Pharma has recently conducted several studies on the impact of chronic hand eczema (CHE). These include the Chronic Hand Eczema epidemiology, Care, and Knowledge of real-life burden, or CHECK study¹, the Real-World trEatment & mAnagement of chronic hand eczema in cLinical practice, or RWEAL study², and the latest survey conducted by Ipsos.³

According to one survey, 65% of dermatology providers surveyed agree there is a lack of education and understanding of CHE. Dermatology Times is breaking down the major findings of these studies, which shed some light on the treatment gaps, diagnostic challenges, and levels of disease burden in patients with moderate to severe CHE.

To read more about research and expert insights into hand eczema, explore our interactive digital supplement featuring an exclusive deep-dive into the state and future of chronic hand eczema care.

References

1. Apfelbacher C, Bewley A, Molin S, et al. Prevalence of Chronic Hand Eczema in adults: A cross-sectional multi-national study of 60,000 respondents in the general population. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #3

2. Gimenez-Arnau AM, Bewley A, Apfelbacher C, et al. Physician-reported treatment patterns in Chronic Hand Eczema – results from the multinational RWEAL medical chart review. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #27

3. LEO Pharma survey: Dermatology providers say chronic hand eczema is widely misunderstood and inadequately managed. BioSpace. March 5, 2025. Accessed June 16, 2025. https://www.biospace.com/press-releases/leo-pharma-survey-dermatology-providers-say-chronic-hand-eczema-is-widely-misunderstood-and-inadequately-managed